A Randomized, Double-blind, Parallel-group Study to Compare Efficacy, Safety, and Immunogenicity of GME751 (Proposed Pembrolizumab Biosimilar) and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 04 Jun 2024
At a glance
- Drugs GME 751 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sandoz
- 28 May 2024 Status changed from not yet recruiting to recruiting.
- 26 Mar 2024 Planned initiation date changed from 28 Feb 2024 to 26 Apr 2024.
- 12 Dec 2023 New trial record